Pricing Log in Create free account

BioAtla, Inc. (BCAB) vs Decoy Therapeutics Inc (DCOY)

BioAtla, Inc. and Decoy Therapeutics Inc are both Biotechnology companies. BioAtla, Inc. and Decoy Therapeutics Inc are of similar size ($2.9M and $2.9M). BioAtla, Inc. has negative trailing earnings, so its P/E is not meaningful; Decoy Therapeutics Inc trades at 0.0×. BioAtla, Inc. grew revenue faster over the last twelve months: 574.7% against −60.5%. BioAtla, Inc. has the higher net margin (−177.2% vs −698.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, BioAtla, Inc. leads on 11 and Decoy Therapeutics Inc on 4.

Valuation

Metric BCAB DCOY Biotechnology median
P/E n/m 0.01 8.50
P/S 0.13 0.30 9.71
P/B n/m 0.14 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.49 0.64
EV/Sales 0.63 (3.48) 9.21
Earnings yield (1,871.32%) 15,691.12% (33.15%)
Free cash flow yield (1,044.09%) (1,677.54%) (25.50%)

Profitability

Metric BCAB DCOY Biotechnology median
Gross margin 95.44% 10.57% 65.16%
Operating margin (180.99%) (706.88%) 0.00%
Net margin (177.21%) (698.79%) 0.00%
Free cash flow margin (132.29%) (432.43%) 0.00%
Return on equity 118.74% (827.77%) (56.36%)
Return on assets (171.72%) (278.04%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCAB DCOY Biotechnology median
Revenue growth (TTM) 574.65% (60.49%) 6.02%
EPS growth (last fiscal year) 29.86% (85.66%) 30.26%
Revenue growth, 5-year CAGR (28.40%) 12.73% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCAB DCOY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.20 1.83 4.72
Net debt to EBITDA 0.12 0.85 0.96

Dividend

Metric BCAB DCOY Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BCAB DCOY Biotechnology median
Market cap 2.89m 2.93m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack